Protocols for management of oral complications of chemotherapy and/or radiotherapy for oral cancer : systematic review and meta-analysis current by Carneiro Neto, José Nunes et al.
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22 (1):e15-23.                                                                                                                                            Management of oral complications of oral cancer
e15
Journal section: Oral Medicine and Pathology
Publication Types: Review
Protocols for management of oral complications of chemotherapy and/or 
radiotherapy for oral cancer: Systematic review and meta-analysis current
José-Nunes Carneiro-Neto 1, Juliana-Dreyer-da-Silva de-Menezes 2, Lucas-Borin Moura 3, Elaine-Maria- 
Sgavioli Massucato 4, Cleverton-Roberto de-Andrade 5
1 Master Student in Dental Science, Diagnostics and Surgery Area, Araraquara Dental School, UNESP - Univ Estadual Pau-
lista, Araraquara, Sao Paulo, Brazil
2 Specialist in Surgery and Traumatology Buco-Maxillofacial by APCD Bauru and the Base Hospital. Master in Rehabilitation 
Sciences at HRAC-USP. Doctoral Student in Dental Science, Diagnostics and Surgery Area, Araraquara Dental School, UN-
ESP - Univ Estadual Paulista, Araraquara, Sao Paulo, Brazil
3 Specialist in Surgery and Traumatology Buco-Maxillofacial by Hospital School of the Federal University of Pelotas. Doctoral 
Student in Dental Science, Diagnostics and Surgery Area, Araraquara Dental School, UNESP - Univ Estadual Paulista, Arar-
aquara, Sao Paulo, Brazil
4 Master and Doctor of Dentistry, Stomatology Area, Araçatuba Dental School, UNESP. Director  and Assistant Professor, 
Department of Diagnostics and Sugery, Araraquara Dental School, UNESP - Univ Estadual Paulista, Araraquara, Sao Paulo, 
Brazil
5 Master in Biopathology Buccodental, Doctor of Stomatology, University of Campinas, Unicamp. Assistant Professor and Pa-
thologist, Department of Physiology and  Pathology, Araraquara Dental School, UNESP - Univ Estadual Paulista, Araraquara, 
Sao Paulo, Brazil
Correspondence:
Universidade Estadual Paulista Júlio de Mesquita Filho 
Faculdade de Odontologia de Araraquara
Departamento de Diagnóstico e Cirurgia
Rua Humaita, 1680, Centro
14801903 - Araraquara
SP - Brasil - Caixa-postal: 331
jnunes.neto@yahoo.com.br
Received: 08/03/2016
Accepted: 15/08/2016
Abstract
Background and Objectives: Considering the high possibility of dentist consult a patient with oral complications 
of chemotherapy and/or radiotherapy for oral cancer because of the advances in this area, this study aims to sys-
tematically review the literature to identify and suggest effective and safe protocols for the managements of oral 
complications in oncology patients.
Material and Methods: The systematic review was designed by PICO and PRISMA including eligibility and ex-
clusion criteria; the source of information and search strategy in PubMed according MeSH: “Mouth Neoplasms 
and Radiotherapy” and “Mouth Neoplasms and Drug Therapy” the period from 2010 to 2015; selection and data 
collection of study was carried form blind and independently by two researchers; risk of bias and methodological 
quality: ensured by the PEDro scale; synthesis of data: of oral complications were evaluated by adapted version of 
associative direction classification proposed by Costigan and collaborators; and data analysis was performed by 
the meta-analysis of BioEstat program (5.0) in the included studies.
Results: 2,700 articles found, 2,371 were selected after removal of duplicate and elected 40 full-text articles. Of 
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these, only 06 articles were included in the systematic review with exclusion of others, per obtain punctuation ≥ 7 
with high methodological quality for synthesis of the managements of oral complications. Since 05 articles were as-
sociated with low risk of bias composing the protocols suggestive for managements and the meta-analysis in odds 
ratio (0.916) to cure and relative risk (1.049) for the development of oral mucositis and pain. 
Conclusions: The protocols suggestive for managements of oral mucositis and pain with MuGard - mucoadhesive hy-
drogel; PerioAid Tratamiento® antiseptic mouthrinse with chlorhexidine and cetylpyridinium chloride; Episil® plus 
benzydamine - bioadhesive oromucosal gel; 0,03% of Triclosan mouthwash Colgate Plax; and Diode Laser Therapy 
of low-level are safe for oncology patients applied according to adopted clinical parameters.
Key words: Oral cancer, radiotherapy, chemotherapy, complications, management.
Introduction
Despite the recent increase in the incidence of Oral Sq-
uamous Cell Carcinoma (OSCC) in younger patients (1) 
and of gender female (2), yet the prevalence is in older 
males (2) between the 5th and 8th decade of life asso-
ciated with high consumption of alcohol and tobacco. 
Since 4% of all oral malignancies are found in patients 
less than 40 years (3).
The OSCC is the most common malignancy of the oral 
cavity with high lethality when diagnosed in tongue and 
floor in advanced stages (3,4), representing 263,000 new 
cases and 127,700 deaths worldwide/year (2). The main 
modalities of contemporary treatments for oral cancer 
include surgical resection, chemotherapy (CT), radio-
therapy (RT) and transplant immunotherapy of hemat-
opoietic stem cells isolated or in combination (5). The 
modalities RT, CT and/or chemoradiotherapy (CRT) 
have a high potential of produce direct damage to tissues 
of the oral cavity or production of haematopoietic cells, 
because these have a high rate of cell turnover between 
7 to 14 days (6). These oral complications are referred 
to as oral mucositis, dysgeusia, infectious diseases (5) 
and xerostomia associated with loss of glandular func-
tion. Together, these oral complications are called Oral 
Complications of Chemotherapy and/or Radiotherapy 
for Oral Cancer (OCCROC) (4). It is clear that high 
prevalence of oral cancer associated with advances in 
detection and application of new treatment modalities 
increase the possibility of the dentist come across, in his 
dental office, with patients presenting clinical condition 
of OCCROC (7). Thereby, we consider important to or-
ganize a study of systematic review of the topic in order 
for systematize and organize published data consider-
ing high methodological quality and low risk of bias and 
so identify and suggest effective and safe protocols for 
the managements of OCCROC in oncology patients. 
Material and Methods
The systematic review was developed according to the 
recommendations of the PRISMA (8), except for pro-
tocol and registration, delimited you for the following 
PICO (patient, intervention, comparison and objective): 
“In patients with OCCROC, current protocols for man-
agement of the experimental group (EG) are safer and 
more effective than the control group (CG) to reduce/
cure these oral complications?”.
- Eligibility criteria
The inclusion criteria for the selection of articles were: 
[1] pattern of publication in a journal or magazine with 
full text online through a Virtual Private Network of 
Paulista State University; [2] search time of publication 
01/01/2010 to 31/05/2015; [3] target population of all age 
groups with staging of oral cancer I-IV; [4] oncological 
treatment with any dose Gray (Gy) to radiotherapy and/
or chemotherapy medication; [5] management compari-
son of EG and CG for OCCROC; [6] Language English; 
and [7] design study of clinical trial. We excluded arti-
cles that did not attend the inclusion criteria.
- Information sources and search strategy
By means of research conducted in electronic databases 
of PubMed, with the following descriptor in English 
according to the MeSH (Medical Subject Headings): 
“Mouth Neoplasms” combined with “and” and quali-
fiers individually “Radiotherapy” and “Drug Therapy”, 
in the period 11 to 15 May 2015.
- Study selection, collection process and data items
Performed independently and blindly by two research-
ers/authors (X and Y) respecting the criteria for inclu-
sion and exclusion previously mentioned. Specifically, 
was performed to identify the search strategy of the ar-
ticles using titles, abstract and full text, collecting the 
following relevant information according to the objec-
tive of the research: primary author and year, country, 
study design, target population, oncological treatment, 
oral complications, managements, follow-up and effec-
tiveness (classified according to three simple rule to the 
results of EG and CG, as poor of 0-16%, bad of 17-33%, 
regular of 34-49%, good of 50-66%, optimum of 67-
82% and excellent of 83-100%).  
- Risk of bias and methodological quality
The quality of the information collected in each selected 
article for the production of systematic literature review 
and protocols suggestive for managements of the the-
matic in question was ensured through the standardi-
zation of PEDro Scale, due to their effectiveness and 
practicability in the article validation (9).
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The criteria of the PEDro Scale were originally devel-
oped to be used in experimental studies in humans, 
standardized on a 0-10 point score for quality of scien-
tific evidence, with punctuation for the following cri-
teria: 1) specification of the inclusion criteria (item not 
punctuated); 2) randomized allocation; 3) confidential-
ity allocation; 4) similarity of groups at baseline or the 
basal phase; 5) blinding subjects; 6) blinding therapist; 
7) blinding evaluator; 8) measure of at least one primary 
outcome in 85% of subjects allocated; 9) analysis of in-
tention to treat; 10) comparison between groups of at 
least one primary outcome and 11) reporting variability 
measures and estimation of the parameters of at least 
one primary variable (9).
For the criteria of exclusion and inclusion examiners 
proceeded the following rule: excluded from the review 
the articles with low [≤ 3 points] and moderate [4-6 
points] methodological quality high and moderate risk 
of bias, respectively, including the others [≥ 7 points] of 
methodological quality high and low risk of bias in the 
systematic review.
- Synthesis of data
Regarding the association of OCCROC with the man-
agement of EG, the studies included in the systematic 
review were evaluated by adapted version of associative 
direction classification proposed by Costigan et al. (10), 
through the association [positive, negative or no] of the 
outcome of management of EG with the indicator of oral 
complications. Pursuing with the codification of the re-
sults between studies equally associated by three simple 
rule of 0-33% as “0” (association without), of 34-59% as 
“?” (indeterminate association) and of 60-100% as “+” 
(positive association) or “–” (negative association). And 
posteriorly with the codification of the low risk of bias 
between four/more studies equally associated with the 
same previous parameter represented by “0 0” (associa-
tion without), “? ?” (indeterminate association) and “+ 
+” (positive association) or “– –” (negative association) 
(11).  This last quality of the studies combined to score 
7-10 points of the PEDro Scale protocols suggestive for 
managements of patients with OCCROC.
- Data analysis
The meta-analysis was performed in BioEstat program 
(5.0) combining the data of the managements of EG and 
CG for oral mucositis and pain (OMP), considering the 
final values of degree and intensity OMP obtained in 
the clinical trials presented in the suggested protocols. 
The degree of homogeneity or heterogeneity of the stud-
ies was evaluated by statistical test Chi-square (χ2) re-
sulting in the acceptance of the null hypothesis (H0) in 
both tests, due the value of P = 0.8985 (homogeneity) 
and P = 0,5299 (heterogeneity) be ≥ to decision level 
α=0.01 and α=0.05, respectively. The H0 of both tests 
applied to studies of this review confirm that the sam-
ples are heterogeneous, in this case, is indicated by the 
data analysis Random Effects Model of DerSimonian-
Laird (12) for evaluation of the following Odds Ratio 
tests (OR) together with the Relative Risk (RR) to quan-
tify the association between the presence of OMP and 
the effectiveness of managements of EG and CG with 
confidence interval of 95% (CI 95%) and decision value 
of OR (P < 0.05) and RR (P < 0.01) for statistical sig-
nificance (13-15).
Results
1- Overview of studies
Were found, according to the eligibility criteria and 
search strategy of the articles in electronic databases of 
PubMed in the period from 11 to 15/05/2015, a total of 
2,700 articles using three descriptors of the MeSH in the 
following association, “Mouth Neoplasms and Radio-
therapy” and “Mouth Neoplasms and Drug Therapy”, 
of which we selected 2,371, removing duplicate articles. 
40 articles were elected containing full text available at 
PubMed for qualification methodology and assessment 
of risk of bias by PEDro Scale. Only 06 articles obtained 
punctuation ≥ 7 with high methodological quality, cri-
teria considered necessary for inclusion this systematic 
review (Fig. 1 and Table 1 and 1 continue).
Of the 06 articles included, five articles obtained punc-
tuation 7 corresponding to RT treatment and an article 
obtained punctuation 9 related to the treatments CRT, re-
spectively (Table 1 and 1 continue). These articles were 
submitted to the adapted version of associative direction 
classification (10), result of the following associations, in 
its most positive, between the index of oral complications 
and the management of EG, but with little positive cod-
ing the results of studies and low risk of bias (Table 2).
2- Risk of bias
The punctuation total of 40 selected articles varies be-
tween 4 and 9, moderate to low risk of bias. Specifically, 
20 articles presented punctuation 4 (RT=11, CT=02 and 
CRT=07), 06 articles punctuation 5 (RT=01, CT=01 and 
CRT=04) and 08 articles punctuation 6 (RT=03, CT=01 
and CRT=04).
The 06 articles identified with low risk of bias demon-
strated study design as clinical trial, prospective, retro-
spective, double-blind, randomized or controlled. And 
according to the direction associative classifications 05 
articles were associated (+ +) with low risk of bias in 
only two indicators of oral complications so composing 
the protocols suggestive for managements of OCCROC 
(Table 3).
3- Synthesis of the managements of OCCROC 
3.1- Oral mucositis
Of the four studies, all positively evaluated the asso-
ciation of oral mucositis with managements of EG 
with punctuation between 7 and 9 in the PEDro Scale 
(clinical trial, prospective, retrospective, double-blind, 
randomized or controlled). The results coding of 80% 
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22 (1):e15-23.                                                                                                                                            Management of oral complications of oral cancer
e18
(+) were checked in the reduction of the degree of oral 
mucositis as indicated in the protocol suggested in ta-
ble 3 through managements with MuGard - mucoad-
hesive hydrogel (13), Diode Laser Therapy of low-level 
of InGaAlP (16), 0,03% of Triclosan mouthwash - Col-
gate Plax (6) and PerioAid Tratamiento® antiseptic 
mouthrinse combined with 0,12% of chlorhexidine and 
0,05% of  cetylpyridinium chloride (17).
3.2- Oral pain
Of the four studies, all positively evaluated the asso-
ciation of oral mucositis with managements of EG 
with punctuation between 7 and 9 in the PEDro Scale 
(clinical trial, retrospective, double-blind, randomized 
or controlled). The codification of studies was 80% (+) 
with positive results in the reducing of the intensity of 
oral pain as indicated by the protocol suggested in table 
3 through managements with MuGard - mucoadhesive 
hydrogel (13), CAM2028 - Episil® plus benzydamine - 
bioadhesive oromucosal gel (14), Diode Laser Therapy 
of low-level of InGaAlP (16) and 0,03% of Triclosan 
mouthwash - Colgate Plax (6).
3.3- Dysphagia
Two studies with 7 and 9 points on the PEDro scale with 
statistical designs of clinical trial, double-blind, rand-
omized or controlled, presented a positive association in 
control of dysphagia with managements of EG, coding 
100% of your results (+) using the MuGard - mucoad-
hesive hydrogel (13) and 0,03% of Triclosan mouthwash 
- Colgate Plax (6) according to the protocol suggested 
in table 3. 
3.4-Xerostomia
A study with 0% coding result (0) association without, 
punctuation 7 on the PEDro scale was related positively 
the association between xerostomia and the use of Peri-
oAid Tratamiento® antiseptic mouthrinse combined 
with 0,12% of chlorhexidine and 0,05% of cetylpyrid-
inium chloride (17) according to the protocol suggested 
in table 3.
3.5- Periodontal infections and fungal
Each oral compilation indicator is not coded by present-
ing only one study with the result of 0% (0). However, 
the study obtained scores 7 points on the PEDro Scale 
(clinical trial, double-blind, randomized and prospec-
tive). Associating yourself positively using PerioAid 
Fig. 1. Flow chart of search strateggy and selection of the articles included in the system-
atic review in accordance with the PRISMA (8)
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Tratamiento® antiseptic mouthrinse combined with 
0,12% of chlorhexidine and 0,05% of cetylpyridinium 
chloride, in the reduction of Candida spp. colonies in 
the oral mucosa and tongue, as well as in samples of 
subgingival periodontal pathogens (P. gingivalis e E. 
corrodens) during the RT (15) according to the protocol 
suggested in table 3. 
4- Meta-analysis
Only five studies were qualified and analyzed with a to-
tal sample of 246 patients. We use effectiveness rates 
of the managements of EG and CG for OMP coming 
from the QT and/or RT OSCC (Table 1 and 1 continue). 
The OR combined demonstrated 0.916, CI 95% = 0.842 
- 0.995, weight of 10.922, χ2 = 0.3271, df = 4, p-value = 
0.0385 and standard error of 0.0426, resulting in statisti-
cally significant in the acceptance of the alternative hy-
pothesis (H1) due the p value of 0.0385 be ≤ to α = 0.05. 
The H1 confirming a higher proportion of effectiveness 
rates of the management of EG for odds ratio in healing 
the OMP, demonstrating 0.9 times greater therapeutic 
efficacy of the studies (13,14,16) compared to their CG 
and managements of the studies (6,17) represented by 
the diamond in the forest plot (Table 2).
The RR combined showed 1.049, CI 95% = 0.360 - 
3.050, weight of 236.094, χ2 = 0.2276, df = 1, p-value = 
0.6333 resulting in the acceptance of the null hypothesis 
(H0) without statistical significance, due the p-value of 
0.6333 be ≥ to α = 0.01. The H0 confirming a relative 
risk of OMP in individuals of both managements of the 
studies (6,13,16,17), showing 1.05 times greater risk of 
developing of OMP in the management of CG of the 
studies (6,13,17) represented by the diamond in the for-
Primary author and 
year Country Study design Target population 
PEDro 
scale 
Oncological 
treatment 
(therapy) 
Allison et al. (13)  
2014 
 
EUA Clinical trial, double-
blind, randomized 
and controlled 
EG: 37 patients with OSCC treated 
surgically, most in stage III and IV 
with a mean age of 58 years; 
CG: 41 patients with OSCC treated 
surgically, most in stage III and IV 
with a mean age of 58 years. 
9 
CRT 
(50-72Gy 
cumulative + 
Cisplatin weekly 
every 3 weeks) 
Hadjieva et al. (14) 
2014  
Bulgaria Clinical trial, double-
blind, randomized 
and controlled 
EG: 20 patients with OSCC treated 
surgically between 32-73 years; 
CG: 18 patients with OSCC treated 
surgically between 32-73 years. 
7 RT (not indicated) 
Lanzós et al. (15) 
2011  
Spain Clinical trial, 
prospective, double-
blind and 
randomized 
EG: 18 patients with OSCC treated 
surgically between 24-72 years; 
CG: 18 patients with OSCC treated 
surgically between 24-75 years. 
Both with at least 10 teeth, smokers, 
chronically ill and without pathology 
of the oral mucosa. 
7 
RT 
(50-80Gy 
cumulative/5 
periods) 
Carvalho et al. (16) 
2011  
Brazil Clinical trial, double-
blind, randomized 
and controlled 
between February 
2008 to December 
2009 
EG: 35 patients (25 male and 10 
female) with OSCC treated 
surgically, most in stage III and IV 
between 22-94 years; 
CG: 35 patients (21 male and 14 
female) with OSCC treated 
surgically, most in stage III and IV 
between 35-79 years. 
7 
RT/CRT 
(60-72Gy 
cumulative + 
Cisplatin 100mg 
every 21 days or 
50mg/week) 
Satheeshkumar et al. (6) 
2010  
Índia Randomized clinical 
trial between January 
to June 2000 
EG: 12 patients (06 male and 06 
women) with OSCC, mean age 63.7 
years; 
CG: 12 patients (06 male and 06 
women) with OSCC, mean age 65.9 
years; 
Both groups without oral deleterious 
habits and not currently treated or 
with surgery earlier, CT or RT 
palliative. 
7 
RT 
(50-52Gy 
cumulative/15 
fractions) 
Lanzós et al. (17) 
2010  
Spain Clinical trial, 
prospective, double-
blind, randomized 
between May 2004 
to May 2007 
EG: 18 patients with OSCC treated 
surgically with a mean age of 54 
years; 
CG: 18 patients with OSCC treated 
surgically with a mean age of 49 
years; 
Both groups have at least 10 teeth, 
oral mucosa without pathology, no 
orthodontic therapy and not pregnant. 
7 
RT 
(50-80Gy 
cumulative/5 
periods) 
!
Table 1.  Characteristics of the studies included in the systematic review (Continue).
Abbreviations: OSCC (Oral Squamous Cell Carcinoma); RT (Radiotherapy); CRT (chemoradiotherapy); EG (experimental group); CG (control 
group); Gy (Absorbed dose in Gray).
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Abbreviations: WHO (World Health Organization); NIC (National Cancer Institute); RTOG (Radiation Therapy Oncology Group); VAS 
(Visual Analogue Scale); IFC (Ingestion of food consistency); BW (Body weight); Gº (degree); Iº (Intensity); DLTLL-InGaALP (Diode Laser 
Therapy of low-level of gallium aluminum–arsenate); CFU (colony forming unit).
!
Oral complications 
(evaluation) 
Managements Follow-up 
during therapy 
Effectiveness 
(nº/total) 
Oral mucositis of Gº ! II = 
ulcerative or more severe 
(WHO) 
 
Oral pain 
 
Dysphagia 
Little weight loss 
 (BW) 
EG: It was used MuGard 
(mucoadhesive hydrogel); 
 
CG: It was used mouthwash 
with saline solution sodium 
bicarbonate. 
 
 
4 weeks Oral mucositis: 
EG-Excellent (89%=33/37 patients); 
CG-Excellent (87%=36/41 patients). 
 
Oral pain: 
EG-Regular (35%=13/37 patients); 
CG-Regular (41%=17/41 patients). 
 
Dysphagia: 
EG- Optimum (78%=29/37 patients); 
CG-Excellent (83%=34/41 patients). 
Oral pain of Iº ! 6 = moderate 
to severe 
(Likert Pain Scale) 
EG: It was used CAM2028 
(Episil®, Camurus) plus 
benzydamine 28,2 mg/mL 
(nonsteroidal anti-
inflammatory) - bioadhesive 
oromucosal gel; 
CG: only CAM2028 (Episil®). 
5 weeks Oral pain: 
EG-Good (65%=13/20 patients); 
CG-Óptimum (69%=12/18 patients). 
 
Fungal infections of Candida 
ssp. and periodontal bacteria 
EG: It was used PerioAid 
Tratamiento® antiseptic 
mouthrinse (Dentaid, 
Cerdanyola del Vallés, Spain) 
combined with 0,12% 
chlorhexidine and 0,05% 
cetylpyridinium chloride; 
  
CG: It was used identical 
placebo to antiseptic mouthrinse 
without the active agents. 
 
 
 4 weeks Fungal infections: 
Oral mucosa 
EG-Excellent (95%=677/7151 ufc); 
CG-Excellent (89%=205/231 ufc). 
Tongue 
EG-Excellent (88%=597/682 ufc); 
CG-Poor (0%=0/17 ufc). 
 
Periodontal infections: 
P. gingivalis 
EG-Excellent (100%=178,679/178,679 ufc); 
CG-Poor (0%=0/161,700 ufc). 
E. corrodens 
EG-Excellent (100%=2,500/2,500 ufc); 
CG-Poor (0%=0/23,760 ufc). 
 Oral mucositis of Gº II = 
erythema with pain, edema or 
ulcer with normal dietary 
intake (NIC) / ulcer erythema 
or not with normal dietary 
intake (WHO) 
 
Oral pain of Iº ! 2 = mild to 
severe (VAS) 
EG: It was used DLTLL-
InGaALP (660 nm, 15 mW, 4 
mm2, 3,8 J/cm2); 
 
CG: It was used DLTLL-
InGaALP (660 nm, 5 mW, 4 
mm2, 1,3 J/cm2). 
 
 
7 weeks Oral mucositis: 
EG-Good (58%=16/35 patients); 
CG-Good (54%=14/35 patients). 
 
Oral pain: 
EG-Excellent (94%=33/35 patients); 
CG-Excellenet (89%=31/35 patients). 
Oral mucositis of Gº I = 
erythematous or not with pain 
and without ulceration (WHO) 
 
Dysphagia 
(IFC/BW) 
 
Oral pain of Iº ! 3 = mild to 
severe (VAS) 
EG: It was used 0,03% of 
Triclosan mouthwash - Colgate 
Plax (M/S Colgate Palmolive 
India Ltd); 
 
CG: It was used 2g of sodium 
bicarbonate powder dissolved in 
warm water. 
 
 
5 weeks Oral mucositis: 
EG-Excellent (89%=11/12 patients); 
CG-Poor (14%=02/12 patients). 
 
Dysphagia: 
Normal diet 
EG=Regular (44%=20/45 dyas); 
CG=Poor (2%=1/45 dyas). 
Weight gain ! 2Kg 
EG-Excellent (100%=45/45 dyas); 
CG-Poor (0%=0/45 dyas). 
Oral pain: 
. EG-Excellent (84%=38/45 dyas); 
CG-Optimum (78%=35/45 dyas). 
Oral mucositis of Gº ! I = 
erythematous with mild pain 
that does not require analgesic 
or more severe (RTOG) 
 
Xerostomia 
(Flow and pH of Saliva) 
EG: It was used PerioAid 
Tratamiento® antiseptic 
mouthrinse (Dentaid, 
Cerdanyola del Vallés, Spain) 
combined with 0,12% 
chlorhexidine and 0,05% 
cetylpyridinium chloride;  
CG: It was used identical 
placebo to antiseptic mouthrinse 
without the active agents. 
4 weeks Oral mucositis: 
EG-Optimum (77%=14/18 patients); 
CG-Optimum (72%=13/18 patients). 
 
Xerostomia: 
Normal salivary flow 
EG-Excellent (94%=17/18 patients); 
CG-Excellent (100%=18/18 patients). 
Neutral pH of saliva 
EG-Excellent (100%=18/18 patients); 
CG-Good (50%=9/18 patients). 
Table 1 continue. Characteristics of the studies included in the systematic review (Conclusión).
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est plot compared to management of CG of the study 
(16) and both managements of the study (14), being that 
the group of 35 patients is the number needed to treat 
(NNT) in the set of management of CG of the studies 
(6,13,16,17) amenable to occur an OMP (Table 2). 
Discussion
- Summary of evidence and limitations
The most of the studies of high methodological quality 
and Low risk of bias according to PEDro Scale (9) and 
the associative direction classification (10) were devel-
Abbreviations: RT (Radiotherapy); CRT (Chemoradiotherapy); X2 (Chi-square); df (Degrees of freedom); NNT (Number needed to treat); OR 
(Odds ratio); RR (Relative risk). Notes: Codification of the results between studies equally associated by three simple rule of 0-33% as “0” 
(association without), of 34-59% as “?” (indeterminate association) and of 60-100% as “+” (positive association) or “–” (negative association). 
codification of the low risk of bias between four/more studies equally associated with “0 0” (association without), “? ?” (indeterminate associa-
tion) and “+ +” (positive association) or “– –” (negative association) according to the PEDro scale.
Table 2. Classification of the studies included in the systematic review with high methodological quality followed by meta-analysis of studies 
with low risk of bias.
Indicator of oral 
complications 
Association to the 
result of the 
management of the 
experimental group 
Primary author and 
year of high-quality 
studies (7-10 points) 
Codification of 
results between 
studies equally 
associated 
Codification of low risk of bias 
between four/more studies equally 
associated 
Oral mucositis Positive 
Positive 
Positive 
Positive 
Allison et al., 2014 
Carvalho et al., 2011 
Satheeshkumar et al., 
2010 Lanzós et al., 
2010 
+ + + 
Oral pain Positive 
Positive 
Positive 
Positive 
Allison et al., 2014 
Hadjieva et al., 2014 
Carvalho et al., 2011 
Satheeshkumar et al., 
2010   
+ + + 
Dysphagia Positive 
Positive 
Satheeshkumar et al., 
2010 
Allison et al., 2014 
+  
Xerostomia Positive Lanzós et al., 2010 0  
Fungal infections Positive Lanzós et al., 2011 0  
Periodontal infections Positive Lanzós et al., 2011 0  
Meta-analysis of 
studies with low risk 
of bias 
OR CI95% 
bottom-
upper 
Weight Florest plot RR CI95% 
bottom-
upper 
Weight Florest plot 
Allison et al., (16) 2014  1,122 0,296-
4,247 
 
20% 
 1,014 0,860-
1,197 
 
59% 
 
Lanzós et al., (20) 2010  1,313 0,308-
5,595 
 
17% 
 1,074 0,734-
1,572 
 
11% 
 
Hadjieva et al., (17) 
2014  
0,936 0,255-
3,441 
 
21% 
 0,977 0,620-
1,540 
 
18% 
 
Carvalho et al., (19) 
2011  
1,295 0,477-
3,512 
 
35% 
 1,138 0,690-
1,876 
 
7% 
 
Sathushkumar et al., (6) 
2010  
1,825 0,204-
16,316 
 
7% 
 1,095 0,787-
1,523 
 
15% 
 
 
Combined 
 
0,916 
0,842-
0,995 
 
100% 
  
1,049 
0,360-
3,050 
 
100% 
 
     
0,3        1,0          5,0 
Favorable to the 
Management  
EG                      CG 
    
0,7         1,0        2,0 
Favorable to the 
Management 
EG                    CG 
Heterogeneity test      !2       df p-value      !2      df p-value  
 0,3271 4 0,0385  0,2276 1 0,6333  
         
Standard error 0,0426    NNT 35   
!
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oped in Spain. The indicators of oral complications em-
anated from oncological patients surgically treated for 
oral cancer during RT were: oral mucositis, oral pain, 
oral dysphagia, xerostomia, periodontal infections and 
fungal; after RT: oral mucositis, oral pain, oral dysphagia 
and xerostomia; during and after CRT: oral mucositis, 
oral pain, oral dysphagia and xerostomia. Being that the 
mucositis, pain and oral dysphagia were emanated only 
to oncological patients during and after RT as a single 
treatment. Regarding protocols of the managements of 
the OCCROC the age of the patients varied between 22 
to 94 years, the contraindication between diseases of 
the oral mucosa and the use of concomitant medication, 
orthodontic therapy, pregnant, currents oral deleterious 
habits and surgery, CT or RT current palliative or ear-
lier, besides the adverse effects in a few patients as nau-
sea, vomiting, upper respiratory tract infection and he-
moptysis. In their majority, in stage III and IV derived 
Abbreviations: OSCC (Oral Squamous Cell Carcinoma); RT (Radiotherapy); CRT (chemoradiotherapy); Gº (degree); Iº (Intensity); WHO 
(World Health Organization); RTOG (Radiation Therapy Oncology Group); NIC (National Cancer Institute); VAS (Visual Analogue Scale).
Primary 
author and 
year 
Indicator of oral 
complications 
Protocols Suggestive 
Allison et al. 
(13) 2014 
Oral mucositis Symptomatic management – MuGard (mucoadhesive hydrogel);  
Indication – oral mucositis of Gº ! II = ulcerative or more severe (WHO); 
Patient – adults with OSCC; 
Age –58 years in mean; 
Stage– III and IV (preferably); 
Oncological treatment performed – surgical and CRT; 
Procedure – mouth rinse with 5mL of mouthwash solution for one minute, 4x/day, during CRT, 
Combined supportive therapy (analgesics, antifungal among other) or not and avoiding eating or 
drinking for an hour after mouth rinse. 
Lanzós et al. 
(17) 2010 
Oral mucositis Symptomatic management – PerioAid Tratamiento® antiseptic mouthrinse (Dentaid, Cerdanyola 
del Vallés, Spain) combined with 0,12% of chlorhexidine and 0,05% of  cetylpyridinium chloride; 
Contraindication – pathologies of concomitant oral mucosa, tobacco, alcoholic beverages, 
orthodontic therapy and pregnant; 
Indication – oral mucositis of Gº ! I = erythematous with mild pain that does not require analgesic 
or more severe (RTOG); 
Patient – adults with OSCC and at least 10 teeth; 
Age – 54 years in mean; 
Stage – not indicated; 
Oncological treatment performed – surgical and RT; 
Procedure – mouth rinse with 15 ml of mouthwash without alcohol, for 30 seconds, 2x/day 
(morning and evening) during 28 days after RT. 
 Hadjieva et al. 
(14) 2014 
Pain oral 
mucositis 
Symptomatic management – CAM2028 (episil®, Camurus) plus 28,2 mg/mL benzydamine 
(nonsteroidal anti-inflammatory) - bioadhesive oromucosal gel;  
Contraindication – use of concomitant medication; 
Adverse effects – nausea and vomiting (07 patients), infection of the upper respiratory tract and 
hemoptysis in a few patients; 
Indication – Oral pain of Iº ! 6 = moderate to severe (Likert Pain Scale); 
Patient – adults with OSCC; 
Age – between 32-73 years; 
Stage – not indicated; 
Oncological treatment performed – surgical and RT; 
Procedure – mouth rinse with 2 ml of the mixture of topical solutions applied in the mouth via 
syringe during 15 seconds, after spitting and avoiding hot food or drink for 3 hours. 
Carvalho et al. 
(16) 2011 
Oral mucositis 
Oral pain 
Symptomatic management – Diode Laser Therapy of low-level of gallium aluminum–arsenate - 
illumination consisted of a continuous 660 nm wavelength, power 15 mW, spot size 4 mm2 and 
energy density delivered to the oral mucosa was 3.8 J/cm2 (Twin laser – MMOptics, MMOptics 
Ltda., São Carlos, São Paulo, Brazil); 
Indication – Prophylactic pre-RT/CRT on the oral mucosa excluding the area of the tumor and 
curative in each oral mucositis of Gº II = erythema with pain, edema or ulcer with normal dietary 
intake (NIC) / ulcer erythema or not with normal dietary intake (WHO), beyond area oral pain of Iº ! 
2 = mild to severe (VAS); 
Patient – adults with OSCC, adequate oral hygiene and topical fluorterapia; 
Age – between 22 - 94 years; 
Stage – III and IV (preferably); 
Oncological treatment performed – surgical and RT/CRT; 
Procedure – applying the laser for 10 seconds daily on the oral mucosa excluding the area of the 
tumor, during 5 consecutive days for 7 weeks before sessions RT/CRT prophylactically and curative 
on each area of mucositis Gº II and oral pain Iº ! 2 developed. 
Satheeshkumar 
et al. (6) 2010 
Oral mucositis 
Oral pain 
Symptomatic management – 0,03% of Triclosan mouthwash - Colgate Plax (M/S Colgate 
Palmolive India Ltd) (Colgate Plax); 
Contraindication – patients with oral deleterious habits and not currently treated or with surgery 
earlier, CT or RT palliative; 
Indication – oral mucositis of Gº I = erythematous or not with pain and without ulceration (WHO) 
and oral pain of Iº ! 3 = mild to severe (VAS); 
Patient – adults with OSCC; 
Age – 63,7 years in mean; 
Stage – not indicated; 
Oncological treatment performed – only RT; 
Procedure – mouth rinse content (not indicated ml) of mouthwash 3x/day, during the end of 
treatment after 45 days RT. 
!
Table 3. Distribution of protocols suggestive for management of oral complications of chemotherapy and / or radiotherapy for oral cancer.
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from surgical oncologic treatment and RT with indicat-
ing mucositis Gº I or II. The managements of EG and 
CG vary over their effectivenesses between good and 
excellent for all indicators of oral complications except 
for the CG to periodontal infection, being that the poor 
effectiveness was detonated only in the management of 
CG for oral mucositis, dysphagia, fungal infections and 
periodontal. However the suggested managements pro-
tocols of OCCROC through the systematic review are 
limited by small samples of the published studies and 
the not evidence of the target population of children, 
adolescents and young. But have low bias risk affirmed 
by PEDro Scale and associative direction classification, 
being suitable for dental practice faithfully in the meth-
odology systematically evaluated.
In the meta-analysis with statistical significance for OR, 
the study of Hadjieva et al., (14) was the one who pre-
sented the management of EG with greater therapeutic 
efficacy and lower risk of development of OMP com-
pared to treatments of other studies (6,13,16,17), being 
that only the study of Carvalho et al., (16) presented a 
higher statistical significance in the analysis of RR of 
management in the GC with therapeutic efficacy lower 
and higher risk of MDO compared to  managements of 
other studies (6,13,14,17). This meta-analysis is limited 
to little combination of current studies on the thematic, 
but it is important for its high quality methodological 
and low risk of bias for dental clinical application, main-
ly of the study of Hadjieva et al., (14) with the protocol 
suggestive for management  with CAM2028 (Episil®, 
Camurus) plus 28,2 mg/mL of benzydamine (nonsteroi-
dal anti-inflammatory) - bioadhesive oromucosal gel for 
adults with pain coming from the oral mucositis of CT 
e/or RT of OSCC (Table 3).
- Implications for future research
The utilization of the protocols suggestive for manage-
ments of OCCROC is safe for non-allergic patients to 
treatment applied according to clinical parameters 
adopted as from the high methodological quality and 
low bias risk of the studies systematically reviewed. For 
future clinical research identified the need to develop 
study designs with more detailed and rigorous methods, 
mainly with the triple-blind blinding, representative 
samples, managements protocols of the OCCROC for 
children, adolescents and young. Of this form, increas-
ing the number of studies with high methodological a 
quality and low risk of bias based on the recommenda-
tions of the clinical trial checklist for the production of 
new managements protocols of the OCCROC complete 
and safe for clinical care in oncology patients. 
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